Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vitamin C + sintilimab + bevacizumab in advanced hepatocellular carcinoma
ChiCTR2500101730Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing High-dose vitamin C + sintilimab + bevacizumab with Sintilimab + bevacizumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ascorbic acidsintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500101730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101730.